干细胞专利价值评估与转移转化对策研究
|
摘要
目的:构建适用于干细胞专利价值评估的指标模型,并对现实场景中除指标内容外影响干细胞专利转移转化的因素进行分析。方法:基于中国技术交易所《专利价值分析指标体系》构建适用于干细胞的专利价值评估体系,采用层次分析法确定权重,通过案例分析验证指标模型的可操作性。结果:基于干细胞的技术特点与指标可操作性构建了适用于干细胞专利价值评估的指标体系,包括技术价值度、市场价值度和法律价值度3个一级指标,技术先进性、技术成熟度、技术成本等9个二级指标,其中,技术先进性、技术成熟度、政策适应性以及市场需求是对干细胞专利价值评估影响力最大的指标。其他因素的分析中,技术核心优势是影响干细胞专利转移转化的关键,此外,技术可行性、质量控制与远期收益均对干细胞技术的成功转移转化有着重要的影响。结论:建立的专利价值评估模型与因素分析可用于干细胞领域的专利价值评估,有助于推动专利技术的有效开发和产业化。
Objective: To construct an indicator model for stem cell patent evaluation and to analyze the factors affecting stem cell patent transfer and transformation in real scenarios besides the indicators. Methods:Based on the Patent Value Analysis Indicator System edited by China Technology Exchange,a patent evaluation system suitable for stem cells patents was constructed. The weight was determined by AHP,and the operability of the indicator model was verified by case analysis. Results: Based on the technical characteristics of stem cell technologies and operability,an indicator system for evaluating stem cell patents was constructed,which included three first-level indicators including technical value,market value and legal value,and nine second-level indicators such as technological advancement,technological maturity,technological cost,et al. Technological advancement,technological maturity,policy adaptability and market demand were the four most influential indicators for the valuation of stem cell patents. In the analysis of other factors,the core advantage of the stem cell technologies was the key to affect the transformation of stem cell patents. In addition,technical feasibility,quality control and long-term benefits also had important impact on the successful transfer and transformation of stem cell technologies. Conclusion: The patent value evaluation model and factor analysis established can be used in stem cell patent evaluation,which is helpful to promote the effective development and industrialization of the patent technology.
Objective: To construct an indicator model for stem cell patent evaluation and to analyze the factors affecting stem cell patent transfer and transformation in real scenarios besides the indicators. Methods:Based on the Patent Value Analysis Indicator System edited by China Technology Exchange,a patent evaluation system suitable for stem cells patents was constructed. The weight was determined by AHP,and the operability of the indicator model was verified by case analysis. Results: Based on the technical characteristics of stem cell technologies and operability,an indicator system for evaluating stem cell patents was constructed,which included three first-level indicators including technical value,market value and legal value,and nine second-level indicators such as technological advancement,technological maturity,technological cost,et al. Technological advancement,technological maturity,policy adaptability and market demand were the four most influential indicators for the valuation of stem cell patents. In the analysis of other factors,the core advantage of the stem cell technologies was the key to affect the transformation of stem cell patents. In addition,technical feasibility,quality control and long-term benefits also had important impact on the successful transfer and transformation of stem cell technologies. Conclusion: The patent value evaluation model and factor analysis established can be used in stem cell patent evaluation,which is helpful to promote the effective development and industrialization of the patent technology.
引文
[1] Meuwissen H J,Gatti R A,Terasaki P I,et al. Treatment of lymphopenic hypogammaglobulinemia and bone-marrow aplasia by transplantation of allogeneic marrow. Crucial role of histocompatiility matching,New England Journal of Medicine,1969,281(13):691-697.
[2] Bacakova L,Zarubova J,Travnickova M,et al. Stem cells:their source,potency and use in regenerative therapies with focus on adipose-derived stem cells-a review. Biotechnology Advances,2018,36(4):1111-1126.
[3] Markets and Markets Editorial Committee. Stem Cell Manufacturing Market by Product(HSCs,MSCs,i PSCs,ESCs,Instruments,Media, Consumables), Application(Research,Target Identification,Therapy(Autologous,Allogeneic),Cell Banks),End User(Pharma,Hospitals)-Global Forecast to2023.[2018-3-31]. https://www. marketsandmarkets. com/Market-Reports/stem-cell-manufacturing-market-70743403. html.
[4]霍国庆.我国科技成果转移转化的根本症结及其解决策略.智库理论与实践,2016,1(2):119-125.Huo G Q. The sticking points and solutions of China’s scientific and technological achievement transformation. Think Tank:Theory&Practice,2016,1(2):119-125.
[5]全国人大常委会.促进科技成果转化法修正案(草案)条文.[2018-3-31]. http://www. npc. gov. cn/npc/xinwen/lfgz/flca/2015-03/02/content_1906948. htm.Standing Committee of the National People’ s Congress.Amendments to the law for promoting the transformation of scientific and technological achievements(Draft).[2018-3-31].http://www. npc. gov. cn/npc/xinwen/lfgz/flca/2015-03/02/content_1906948. htm.
[6]中国技术交易所.专利价值分析指标体系操作手册.北京:知识产权出版社,2012:5-32.China Technology Exchange. Operating manual of patent value analysis index system. Beijing:Intellectual Property Publishing House,2012:5-32.
[7]de Alvarenga E C,Silva W N,Vasconcellos R,et al. Promyelocytic leukemia protein in mesenchymal stem cells is essential for leukemia progression. Annals of Hematology,2018,97(10):1749-1755.
[8] Cao N,Liao T L,Liu J J,et al. Clinical-grade human umbilical cord-derived mesenchymal stem cells reverse cognitive aging via improving synaptic plasticity and endogenous neurogenesis. Cell Death&Disease,8(8):e2996.
[9]高歌,崔东.我国首批胚胎干细胞临床研究项目今日启动.[2017-4-11]. http://politics. people. com. cn/n1/2017/0411/c1001-29202930. html.Gao G,Cui D. The first clinical research projects on embryonic stem cells in China were launched today.[2017-4-11]. http://politics. people. com. cn/n1/2017/0411/c1001-29202930. html.
[10]丁建业,陆毅.专利评估与层次分析法(AHP).专利文献研究,2007,6:1-7.Ding J Y,Lu Y. Patent evaluation and analytic hierarchy process(AHP). Patent Literature Research,2007,6:1-7.
[11] Qiu X X,Liu Y,Zhang Y F,et al. Rapamycin and CHIR99021coordinate robust cardiomyocyte differentiation from human pluripotent stem cells via reducing p53-dependent apoptosis.Journal of the American Heart Association,2017,10(6):e005295.
[12] Lu Q,Liu Y A,Wang Y,et al. Rapamycin efficiently promotes cardiac differentiation of mouse embryonic stem cells.[2017-6-7]. http://www. bioscirep. org/content/ppbioscirep/37/3/BSR20160552. full. pdf.
[13]厦门大学.利用小分子化合物诱导干细胞向心肌分化的方法:中国. CN104447417A. 2015-03-25[2018-08-18]. http://www.pss-system. gov. cn/sipopublicsearch/patentsearch/showViewListjumpToView. shtml.Xiamen University. Method for inducing cardiac differentiation of stem cells by utilizing small molecule compounds.CN104447417A. 2015-03-25[2018-08-18]. http://www. psssystem. gov. cn/sipopublicsearch/patentsearch/showViewListjumpToView. shtml.
[2] Bacakova L,Zarubova J,Travnickova M,et al. Stem cells:their source,potency and use in regenerative therapies with focus on adipose-derived stem cells-a review. Biotechnology Advances,2018,36(4):1111-1126.
[3] Markets and Markets Editorial Committee. Stem Cell Manufacturing Market by Product(HSCs,MSCs,i PSCs,ESCs,Instruments,Media, Consumables), Application(Research,Target Identification,Therapy(Autologous,Allogeneic),Cell Banks),End User(Pharma,Hospitals)-Global Forecast to2023.[2018-3-31]. https://www. marketsandmarkets. com/Market-Reports/stem-cell-manufacturing-market-70743403. html.
[4]霍国庆.我国科技成果转移转化的根本症结及其解决策略.智库理论与实践,2016,1(2):119-125.Huo G Q. The sticking points and solutions of China’s scientific and technological achievement transformation. Think Tank:Theory&Practice,2016,1(2):119-125.
[5]全国人大常委会.促进科技成果转化法修正案(草案)条文.[2018-3-31]. http://www. npc. gov. cn/npc/xinwen/lfgz/flca/2015-03/02/content_1906948. htm.Standing Committee of the National People’ s Congress.Amendments to the law for promoting the transformation of scientific and technological achievements(Draft).[2018-3-31].http://www. npc. gov. cn/npc/xinwen/lfgz/flca/2015-03/02/content_1906948. htm.
[6]中国技术交易所.专利价值分析指标体系操作手册.北京:知识产权出版社,2012:5-32.China Technology Exchange. Operating manual of patent value analysis index system. Beijing:Intellectual Property Publishing House,2012:5-32.
[7]de Alvarenga E C,Silva W N,Vasconcellos R,et al. Promyelocytic leukemia protein in mesenchymal stem cells is essential for leukemia progression. Annals of Hematology,2018,97(10):1749-1755.
[8] Cao N,Liao T L,Liu J J,et al. Clinical-grade human umbilical cord-derived mesenchymal stem cells reverse cognitive aging via improving synaptic plasticity and endogenous neurogenesis. Cell Death&Disease,8(8):e2996.
[9]高歌,崔东.我国首批胚胎干细胞临床研究项目今日启动.[2017-4-11]. http://politics. people. com. cn/n1/2017/0411/c1001-29202930. html.Gao G,Cui D. The first clinical research projects on embryonic stem cells in China were launched today.[2017-4-11]. http://politics. people. com. cn/n1/2017/0411/c1001-29202930. html.
[10]丁建业,陆毅.专利评估与层次分析法(AHP).专利文献研究,2007,6:1-7.Ding J Y,Lu Y. Patent evaluation and analytic hierarchy process(AHP). Patent Literature Research,2007,6:1-7.
[11] Qiu X X,Liu Y,Zhang Y F,et al. Rapamycin and CHIR99021coordinate robust cardiomyocyte differentiation from human pluripotent stem cells via reducing p53-dependent apoptosis.Journal of the American Heart Association,2017,10(6):e005295.
[12] Lu Q,Liu Y A,Wang Y,et al. Rapamycin efficiently promotes cardiac differentiation of mouse embryonic stem cells.[2017-6-7]. http://www. bioscirep. org/content/ppbioscirep/37/3/BSR20160552. full. pdf.
[13]厦门大学.利用小分子化合物诱导干细胞向心肌分化的方法:中国. CN104447417A. 2015-03-25[2018-08-18]. http://www.pss-system. gov. cn/sipopublicsearch/patentsearch/showViewListjumpToView. shtml.Xiamen University. Method for inducing cardiac differentiation of stem cells by utilizing small molecule compounds.CN104447417A. 2015-03-25[2018-08-18]. http://www. psssystem. gov. cn/sipopublicsearch/patentsearch/showViewListjumpToView. shtml.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |